Destiny Pharma PLC teams up with US Department of Veterans Affairs to find ‘new attributes’ for its next-generation antibiotic
NTCD-M3 is staying formulated to combat Clostridioides difficile bacterial infections (CDI) in the intestine ()
NTCD-M3 is staying formulated to combat Clostridioides difficile bacterial infections (CDI) in the intestine ()